Stock VRPX VIRPAX PHARMACEUTICALS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Virpax Pharmaceuticals, Inc. Stock

Equities

VRPX

US9282512063

Biotechnology & Medical Research

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-05-31 pm EDT 		5-day change 1st Jan Change
0.7 USD -3.77% Intraday chart for Virpax Pharmaceuticals, Inc. -3.43% -78.13%
May. 22 Maxim Downgrades Virpax Pharmaceuticals to Hold From Buy MT
May. 15 Virpax Prices Public Offering of Shares, Warrants; Shares Tumble MT

Financials (USD)

Sales 2024 * - Sales 2025 * - Capitalization 820K
Net income 2024 * -12M Net income 2025 * -15M EV / Sales 2024 * -
Net cash position 2024 * - Net cash position 2025 * - EV / Sales 2025 * -
P/E ratio 2024 *
-0.12 x
P/E ratio 2025 *
-0.31 x
Employees 7
Yield 2024 *
-
Yield 2025 *
-
Free-Float 85.71%
More Fundamentals * Assessed data

Chart Virpax Pharmaceuticals, Inc.

Dynamic Chart

Latest news about Virpax Pharmaceuticals, Inc.

Maxim Downgrades Virpax Pharmaceuticals to Hold From Buy MT
Virpax Prices Public Offering of Shares, Warrants; Shares Tumble MT
Top Premarket Decliners MT
Investors Await Key Inflation Data for April as US Futures Remain Flat in Wednesday's Premarket MT
Virpax Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Virpax Pharmaceuticals, Inc. Announces Resignation of Jeffrey Gudin as Chief Medical Officer and Executive Vice President CI
Virpax Pharmaceuticals, Inc. Announces Results of Maximum Tolerated Dose Study for Probudur CI
Virpax Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Scilex Settles Claims in Case Against Virpax for $6 Million, 6% Royalties From Three Drugs MT
Virpax Pharmaceuticals Announces Preliminary Results of Probudurtm Pilot Study with the U.S. Army Institute of Surgical Research CI
Virpax Pharmaceuticals Stockholders Approve Reverse Stock Split Plan; Shares Fall MT
Virpax Pharmaceuticals Announces Leadership Transition CI
Virpax Pharmaceuticals, Inc. Announces CEO Changes CI
Virpax Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Virpax Pharmaceuticals Announces Envelta Remains on Track for Trial in Humans Following FDA Review CI
More news

Analyst Recommendations on Virpax Pharmaceuticals, Inc.

Maxim Downgrades Virpax Pharmaceuticals to Hold From Buy MT
Analysis-Biotech IPOs to bloom with spotlight on startups with human trial data RE
Maxim Group Initiates Coverage on Virpax Pharmaceuticals With Buy Rating, $4 Price Target MT
More recommendations

Press releases Virpax Pharmaceuticals, Inc.

Virpax Pharmaceuticals to Present at 2024 BIO International Convention AQ
Virpax® Pharmaceuticals to Present at 2024 BIO International Convention BU
Virpax Announces Pricing of $2.25 Million Public Offering BU
Virpax Pharmaceuticals Reports 2024 First Quarter Results and Recent Developments BU
Virpax Announces Results of Maximum Tolerated Dose Study for Probudur AQ
More press releases

News in other languages on Virpax Pharmaceuticals, Inc.

Altasciences von Virpax ausgewählt, um die Entwicklung eines neuen Medikaments zur Verhinderung der Ausbreitung von grippeähnlichen Viren zu unterstützen
Altasciences choisi par Virpax pour soutenir le développement d'un nouveau médicament pour empêcher la propagation de virus apparentés à la grippe
Virpax Pharmaceuticals étend ses droits de développement et de commercialisation d'AnQlar™ par un accord de licence mondial
Virpax Pharmaceuticals erweitert seine Entwicklungs- und Vermarktungsrechte an AnQlar™ mit weltweiter Lizenzvereinbarung
Altasciences a été choisie par Virpax Pharmaceuticals, Inc. pour mener les premiers essais cliniques chez l'humain portant sur l'Epoladerm™ en vue de traiter les douleurs chroniques associées à l'arthrose du genou
More news

Quotes and Performance

1 day-3.77%
1 week-3.43%
1 month-73.58%
3 months-77.06%
6 months-82.49%
Current year-78.13%
More quotes

Highs and lows

1 week
0.65
Extreme 0.649
0.74
1 month
0.63
Extreme 0.6316
3.14
Current year
0.63
Extreme 0.6316
5.48
1 year
0.63
Extreme 0.6316
11.77
3 years
0.63
Extreme 0.6316
360.00
5 years
0.63
Extreme 0.6316
360.00
10 years
0.63
Extreme 0.6316
360.00
More quotes

Managers and Directors - Virpax Pharmaceuticals, Inc.

Managers TitleAgeSince
Jeffrey Gudin FOU
 Founder 58 16-12-31
Gerald Bruce CEO
 Chief Executive Officer 68 17-07-31
Vinay Shah DFI
 Director of Finance/CFO 62 23-06-19
Members of the board TitleAgeSince
Gerald Bruce CEO
 Chief Executive Officer 68 17-07-31
Jeffrey Gudin FOU
 Founder 58 16-12-31
Barbara A. Ruskin BRD
 Director/Board Member - 23-03-23
More insiders

Quotes

Date Price Change Volume
24-05-31 0.7 -3.77% 65,983
24-05-30 0.7274 -0.33% 22,393
24-05-29 0.7298 +2.64% 29,068
24-05-28 0.711 -1.92% 51,598
24-05-24 0.7249 +0.68% 49,567

Delayed Quote Nasdaq, May 31, 2024 at 04:00 pm EDT

More quotes

Company Profile

Virpax Pharmaceuticals, Inc. is a preclinical-stage pharmaceutical company. The Company is focused on developing novel and proprietary drug delivery systems across various pain indication. Its drug-delivery systems and drug-releasing technologies being developed are focused on advancing non-opioid and non-addictive pain management treatments and treatments for central nervous system (CNS) disorders to enhance patients’ quality of life. Its portfolio consists of multiple preclinical stage product candidates: Epoladerm, Probudur, Envelta, AnQlar and NobrXiol. Probudur is a single injection liposomal bupivacaine formulation being developed to manage post-operative pain. Envelta is an intranasal molecular envelope enkephalin formulation being developed to manage acute and chronic pain, including pain associated with cancer. The NobrXiol is being developed for the nasal delivery of a pharmaceutical-grade cannabidiol (CBD) for the management of rare pediatric epilepsy.
Sector
Biotechnology & Medical Research
Calendar
2024-06-03 - Bio International Convention
More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
1
Last Close Price
0.7 USD
Average target price
20 USD
Spread / Average Target
+2,757.14%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
VIRPAX PHARMACEUTICALS, INC. Stock Virpax Pharmaceuticals, Inc.
-78.13% 820K
MODERNA, INC. Stock Moderna, Inc.
+43.36% 54.64B
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
-5.31% 39.92B
LONZA GROUP AG Stock Lonza Group AG
+37.52% 38.82B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+14.75% 26.86B
CELLTRION, INC. Stock Celltrion, Inc.
-12.56% 26.22B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-22.45% 18.78B
BIO-TECHNE CORPORATION Stock Bio-Techne Corporation
+0.04% 12.16B
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+25.12% 12.21B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+26.04% 11.94B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. VRPX Stock